Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. (ACRS) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
acrs · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Aclaris Therapeutics, Inc. (ACRS) measures how much investors pay for each dollar of the company's trailing earnings. ACRS's current PE ratio of N/A is calculated by dividing its stock price of $4.36 by its TTM earnings per share of -$0.54.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2013 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Aclaris Therapeutics, Inc.You ACRS | $526M | N/A | — | -$0.54 |
 Allogene Therapeutics, Inc. ALLO | $451M | N/A | — | -$0.87 |
 BioAge Labs, Inc. BIOA | $584M | N/A | — | -$2.24 |
 Cabaletta Bio, Inc. CABA | $522M | N/A | — | -$1.64 |
 Editas Medicine, Inc. EDIT | $259M | N/A | — | -$1.80 |
 908 Devices Inc. MASS | $306M | N/A | — | -$1.01 |
 MDxHealth S.A. MDXH | $28M | N/A | — | -$0.67 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.53 | — | |
2024-12-31 FY2024 | — | $-1.71 | — | |
2023-12-31 FY2023 | — | $-1.27 | — | |
2022-12-31 FY2022 | — | $-1.33 | — | |
2021-12-31 FY2021 | — | $-1.60 | — | |
2020-12-31 FY2020 | — | $-1.20 | — | |
2019-12-31 FY2019 | — | $-3.90 | — | |
2018-12-31 FY2018 | — | $-4.03 | — | |
2017-12-31 FY2017 | — | $-2.44 | — | |
2016-12-31 FY2016 | — | $-2.25 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Aclaris Therapeutics, Inc. (ACRS) measures how much investors pay for each dollar of the company's trailing earnings. ACRS's current PE ratio of N/A is calculated by dividing its stock price of $4.36 by its TTM earnings per share of -$0.54.
Frequently asked questions
ACRS pe ratio · 6 questionsACRS's current PE ratio is N/A as of 2026-06-08, based on a stock price of $4.36 and TTM EPS of -$0.54. Data sourced from Financial Modeling Prep via ACRS's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Aclaris Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08